Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. [electronic resource]
Producer: 20130523Description: 536 p. digitalISSN:- 1471-2407
- Adult
- Aged
- Aldehyde Oxidase -- genetics
- Area Under Curve
- Cytochrome P-450 CYP2D6 -- genetics
- DNA Damage
- Dipeptides -- adverse effects
- Dose-Response Relationship, Drug
- Female
- Glucuronosyltransferase -- genetics
- Heterocyclic Compounds, 4 or More Rings -- adverse effects
- Humans
- Infusions, Intravenous
- Male
- Metabolic Clearance Rate
- Middle Aged
- Molecular Structure
- Neoplasms -- drug therapy
- Pharmacogenetics -- methods
- Polymorphism, Genetic
- Prodrugs -- adverse effects
- Thrombocytopenia -- chemically induced
- Topoisomerase I Inhibitors -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.